Elizabeth Chertow Santarsiero

Real-world (RW) analysis of characteristics and risk of recurrence (ROR) in Black patients (pts) with HR+/HER2− early breast cancer (EBC) eligible for NATALEE.

Yara George Abdou, Sonya Reid, Komal L. Jhaveri, Mark Daniel Pegram et autres

527 Background: The NATALEE trial showed statistically significant and clinically meaningful invasive disease–free survival benefit with ribociclib + nonsteroidal aromatase inhibitor (NSAI) vs NSAI alone in pts with stage II/III HR+/HER2− EBC at high ROR that deepened even after all pts were …

us, ch (code pays fourni par la source)

Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in NATALEE: Analysis across menopausal status and age.

Kevin M. Kalinsky, Mattea Reinisch, Yen‐Shen Lu, Marc Debled et autres

516 Background: The NATALEE trial demonstrated significant invasive disease–free survival benefit with RIB + NSAI vs NSAI alone in patients (pts) with stage II/III HR+/HER2− early breast cancer (EBC) at high risk of recurrence. Here, we report outcomes by menopausal status and …

us, de, tw, fr, cn, au, ch, ie, in, kr (code pays fourni par la source)

Real-world impact of breast cancer recurrence: Understanding patient and caregiver perspectives in the United States through social media analysis.

Sue Weldon, Megan-Claire Chase, Megan Rutt, Elizabeth Chertow Santarsiero et autres

e23277 Background: There is limited published evidence on the experiences of patients and caregivers in the USA related to early breast cancer (eBC) risk of recurrence (RoR). This analysis aimed to gain insight on patient and caregiver awareness of RoR, discussions with …

us, in (code pays fourni par la source)

245P Characteristics of real-world (RW) NATALEE and monarchE eligible populations: A US electronic health records (EHR) database analysis

Paolo Tarantino, H.S. Rugo, G. Curigliano, Joyce A O'Shaughnessy et autres

us, it, de, ch, gb (code pays fourni par la source)

Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2− early breast cancer (EBC) treated with endocrine therapy (ET) in the US.

Pedram Razavi, Mehnaj Ahmed, Ashley Roush, Rohan C. Parikh et autres

e12533 Background: Despite improved management of HR+/HER2− EBC, pts experience recurrences while on or up to decades after ending standard-of-care (SOC) ET. Addition of adjuvant (adj) cyclin-dependent kinase 4/6 inhibitors (CDK4/6is), ribociclib and abemaciclib, to SOC ET resulted in significant improvement of …

us (code pays fourni par la source)